This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsYooma Wellness（7AI）株式概要Engages in the manufacturing, marketing, distribution, and sale of wellness products in Canada, Europe, Japan, China, and the United States. 詳細7AI ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬過去 1 年間で収益は186.5%増加しましたリスク分析意味のある時価総額がありません ( €343K )株式の流動性は非常に低い 最新の財務報告は6か月以上前のものである すべてのリスクチェックを見る7AI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.000599.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-29m14m2016201920222025202620282031Revenue US$14.2mEarnings US$1.5mAdvancedSet Fair ValueView all narrativesYooma Wellness Inc. 競合他社Astrid IntelligenceSymbol: OFEX:ASTRMarket cap: UK£5.7mNeutriSci InternationalSymbol: TSXV:NU.HMarket cap: CA$892.1kBioAdaptivesSymbol: OTCPK:BDPTMarket cap: US$40.8kKoios BeverageSymbol: CNSX:FITMarket cap: CA$473.6k価格と性能株価の高値、安値、推移の概要Yooma Wellness過去の株価現在の株価CA$0.000552週高値CA$0.000552週安値CA$0.0005ベータ2.731ヶ月の変化0%3ヶ月変化0%1年変化0%3年間の変化n/a5年間の変化n/aIPOからの変化-99.92%最新ニュースお知らせ • Oct 01Yooma Wellness May Be Subject to Delisting from or Other Remedies by One or Both of the ExchangesYooma Wellness Inc. (Company) announced that its wholly-owned subsidiary Yooma Europe Limited (“Yooma Europe”) has completed the sale of Birmingham-based Vitality CBD Limited (“Vitality”), a UK-focused CBD company, for a total consideration of $2.0 million (the “Disposal”) to Psilobrain Therapeutics Inc. (“Psilobrain”). The Company has faced and is continuing to face significant financial and operational challenges and liquidity constraints which have gradually increased in severity over the last year. With the completion of the Disposal, the Company no longer has any material operating business lines or revenue generating assets. While the Company is continuing to consider all available alternatives, as set out in greater detail in the Company’s press release dated February 9, 2023, there can be no assurance at this time that the Company will be successful in addressing its liquidity constraints on a timely basis or at all. If the Company is unable to secure additional sources of liquidity, it is anticipated that the Company will have no alternative other than to pursue a liquidation, winding-up or insolvency proceeding. As a consequence of the challenges and liquidity constraints faced by the Company, it has fallen out of compliance with its continuous disclosure obligations and with a number of the rules and policies of the Canadian Securities Exchange and the AQUIS Growth Market (the “Exchanges”). The Company has been subject to a cease-trade order issued by the Ontario Securities Commission since May 8, 2023, resulting from the Company’s inability to file its annual financial statements, management discussion and analysis and CEO and CFO certifications for the year ended December 31, 2022, and its common shares have also been suspended from trading on the Canadian Securities Exchange and the AQUIS Growth Market since that date. Based on the Company’s current financial condition and the anticipated proceeds of the Disposal, the Company no longer expects that it will be able to complete the steps necessary to lift the cease trade order on a timely basis or at all, and notes that it may be subject to delisting from or other remedies by one or both of the Exchanges.Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Feb 10Yooma Announces an Exit from Japan and Wind-Down of OperationsYooma Wellness Inc. provided a corporate update. The Company is engaged in an ongoing operational restructuring aimed at addressing depressed market conditions in the CBD wellness industry, the Company's increasing liquidity constraints and lack of working capital. The initial phases of this restructuring involved the wind-down of the Company's operations in the United States last year, and has gradually expanded to include the Company's operations in other unprofitable markets. In parallel with these restructuring initiatives, the Company has also been engaged in a continuing review of strategic alternatives for the Company, however, that process has to date been unsuccessful in identifying a path forward.Reported Earnings • Dec 01Third quarter 2022 earnings released: US$0.006 loss per share (vs US$0.034 loss in 3Q 2021)Third quarter 2022 results: US$0.006 loss per share (improved from US$0.034 loss in 3Q 2021). Revenue: US$2.42m (up 14% from 3Q 2021). Net loss: US$624.8k (loss narrowed 76% from 3Q 2021).Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 31Second quarter 2022 earnings released: US$0.011 loss per share (vs US$0.042 loss in 2Q 2021)Second quarter 2022 results: US$0.011 loss per share (up from US$0.042 loss in 2Q 2021). Revenue: US$3.29m (up 51% from 2Q 2021). Net loss: US$1.13m (loss narrowed 65% from 2Q 2021).最新情報をもっと見るRecent updatesお知らせ • Oct 01Yooma Wellness May Be Subject to Delisting from or Other Remedies by One or Both of the ExchangesYooma Wellness Inc. (Company) announced that its wholly-owned subsidiary Yooma Europe Limited (“Yooma Europe”) has completed the sale of Birmingham-based Vitality CBD Limited (“Vitality”), a UK-focused CBD company, for a total consideration of $2.0 million (the “Disposal”) to Psilobrain Therapeutics Inc. (“Psilobrain”). The Company has faced and is continuing to face significant financial and operational challenges and liquidity constraints which have gradually increased in severity over the last year. With the completion of the Disposal, the Company no longer has any material operating business lines or revenue generating assets. While the Company is continuing to consider all available alternatives, as set out in greater detail in the Company’s press release dated February 9, 2023, there can be no assurance at this time that the Company will be successful in addressing its liquidity constraints on a timely basis or at all. If the Company is unable to secure additional sources of liquidity, it is anticipated that the Company will have no alternative other than to pursue a liquidation, winding-up or insolvency proceeding. As a consequence of the challenges and liquidity constraints faced by the Company, it has fallen out of compliance with its continuous disclosure obligations and with a number of the rules and policies of the Canadian Securities Exchange and the AQUIS Growth Market (the “Exchanges”). The Company has been subject to a cease-trade order issued by the Ontario Securities Commission since May 8, 2023, resulting from the Company’s inability to file its annual financial statements, management discussion and analysis and CEO and CFO certifications for the year ended December 31, 2022, and its common shares have also been suspended from trading on the Canadian Securities Exchange and the AQUIS Growth Market since that date. Based on the Company’s current financial condition and the anticipated proceeds of the Disposal, the Company no longer expects that it will be able to complete the steps necessary to lift the cease trade order on a timely basis or at all, and notes that it may be subject to delisting from or other remedies by one or both of the Exchanges.Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Feb 10Yooma Announces an Exit from Japan and Wind-Down of OperationsYooma Wellness Inc. provided a corporate update. The Company is engaged in an ongoing operational restructuring aimed at addressing depressed market conditions in the CBD wellness industry, the Company's increasing liquidity constraints and lack of working capital. The initial phases of this restructuring involved the wind-down of the Company's operations in the United States last year, and has gradually expanded to include the Company's operations in other unprofitable markets. In parallel with these restructuring initiatives, the Company has also been engaged in a continuing review of strategic alternatives for the Company, however, that process has to date been unsuccessful in identifying a path forward.Reported Earnings • Dec 01Third quarter 2022 earnings released: US$0.006 loss per share (vs US$0.034 loss in 3Q 2021)Third quarter 2022 results: US$0.006 loss per share (improved from US$0.034 loss in 3Q 2021). Revenue: US$2.42m (up 14% from 3Q 2021). Net loss: US$624.8k (loss narrowed 76% from 3Q 2021).Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 31Second quarter 2022 earnings released: US$0.011 loss per share (vs US$0.042 loss in 2Q 2021)Second quarter 2022 results: US$0.011 loss per share (up from US$0.042 loss in 2Q 2021). Revenue: US$3.29m (up 51% from 2Q 2021). Net loss: US$1.13m (loss narrowed 65% from 2Q 2021).Board Change • May 26No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Sep 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元7AIDE Personal ProductsDE 市場7D0%-1.7%0.6%1Y0%-5.2%3.8%株主還元を見る業界別リターン: 7AI過去 1 年間で-5.2 % の収益を上げたGerman Personal Products業界を下回りました。リターン対市場: 7AIは、過去 1 年間で3.8 % のリターンを上げたGerman市場を下回りました。価格変動Is 7AI's price volatile compared to industry and market?7AI volatility7AI Average Weekly Movementn/aPersonal Products Industry Average Movement5.2%Market Average Movement5.8%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.8%安定した株価: 7AI 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間の7AIのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aJordan Greenbergyooma.caもっと見るYooma Wellness Inc. 基礎のまとめYooma Wellness の収益と売上を時価総額と比較するとどうか。7AI 基礎統計学時価総額€342.61k収益（TTM）-€26.61m売上高(TTM)€12.86m0.0xP/Sレシオ0.0xPER（株価収益率7AI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7AI 損益計算書（TTM）収益US$14.19m売上原価US$10.14m売上総利益US$4.05mその他の費用US$33.41m収益-US$29.36m直近の収益報告Sep 30, 2022次回決算日該当なし一株当たり利益（EPS）-0.29グロス・マージン28.52%純利益率-206.96%有利子負債／自己資本比率90.3%7AI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/04 19:33終値2023/05/08 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Yooma Wellness Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 01Yooma Wellness May Be Subject to Delisting from or Other Remedies by One or Both of the ExchangesYooma Wellness Inc. (Company) announced that its wholly-owned subsidiary Yooma Europe Limited (“Yooma Europe”) has completed the sale of Birmingham-based Vitality CBD Limited (“Vitality”), a UK-focused CBD company, for a total consideration of $2.0 million (the “Disposal”) to Psilobrain Therapeutics Inc. (“Psilobrain”). The Company has faced and is continuing to face significant financial and operational challenges and liquidity constraints which have gradually increased in severity over the last year. With the completion of the Disposal, the Company no longer has any material operating business lines or revenue generating assets. While the Company is continuing to consider all available alternatives, as set out in greater detail in the Company’s press release dated February 9, 2023, there can be no assurance at this time that the Company will be successful in addressing its liquidity constraints on a timely basis or at all. If the Company is unable to secure additional sources of liquidity, it is anticipated that the Company will have no alternative other than to pursue a liquidation, winding-up or insolvency proceeding. As a consequence of the challenges and liquidity constraints faced by the Company, it has fallen out of compliance with its continuous disclosure obligations and with a number of the rules and policies of the Canadian Securities Exchange and the AQUIS Growth Market (the “Exchanges”). The Company has been subject to a cease-trade order issued by the Ontario Securities Commission since May 8, 2023, resulting from the Company’s inability to file its annual financial statements, management discussion and analysis and CEO and CFO certifications for the year ended December 31, 2022, and its common shares have also been suspended from trading on the Canadian Securities Exchange and the AQUIS Growth Market since that date. Based on the Company’s current financial condition and the anticipated proceeds of the Disposal, the Company no longer expects that it will be able to complete the steps necessary to lift the cease trade order on a timely basis or at all, and notes that it may be subject to delisting from or other remedies by one or both of the Exchanges.
Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Feb 10Yooma Announces an Exit from Japan and Wind-Down of OperationsYooma Wellness Inc. provided a corporate update. The Company is engaged in an ongoing operational restructuring aimed at addressing depressed market conditions in the CBD wellness industry, the Company's increasing liquidity constraints and lack of working capital. The initial phases of this restructuring involved the wind-down of the Company's operations in the United States last year, and has gradually expanded to include the Company's operations in other unprofitable markets. In parallel with these restructuring initiatives, the Company has also been engaged in a continuing review of strategic alternatives for the Company, however, that process has to date been unsuccessful in identifying a path forward.
Reported Earnings • Dec 01Third quarter 2022 earnings released: US$0.006 loss per share (vs US$0.034 loss in 3Q 2021)Third quarter 2022 results: US$0.006 loss per share (improved from US$0.034 loss in 3Q 2021). Revenue: US$2.42m (up 14% from 3Q 2021). Net loss: US$624.8k (loss narrowed 76% from 3Q 2021).
Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 31Second quarter 2022 earnings released: US$0.011 loss per share (vs US$0.042 loss in 2Q 2021)Second quarter 2022 results: US$0.011 loss per share (up from US$0.042 loss in 2Q 2021). Revenue: US$3.29m (up 51% from 2Q 2021). Net loss: US$1.13m (loss narrowed 65% from 2Q 2021).
お知らせ • Oct 01Yooma Wellness May Be Subject to Delisting from or Other Remedies by One or Both of the ExchangesYooma Wellness Inc. (Company) announced that its wholly-owned subsidiary Yooma Europe Limited (“Yooma Europe”) has completed the sale of Birmingham-based Vitality CBD Limited (“Vitality”), a UK-focused CBD company, for a total consideration of $2.0 million (the “Disposal”) to Psilobrain Therapeutics Inc. (“Psilobrain”). The Company has faced and is continuing to face significant financial and operational challenges and liquidity constraints which have gradually increased in severity over the last year. With the completion of the Disposal, the Company no longer has any material operating business lines or revenue generating assets. While the Company is continuing to consider all available alternatives, as set out in greater detail in the Company’s press release dated February 9, 2023, there can be no assurance at this time that the Company will be successful in addressing its liquidity constraints on a timely basis or at all. If the Company is unable to secure additional sources of liquidity, it is anticipated that the Company will have no alternative other than to pursue a liquidation, winding-up or insolvency proceeding. As a consequence of the challenges and liquidity constraints faced by the Company, it has fallen out of compliance with its continuous disclosure obligations and with a number of the rules and policies of the Canadian Securities Exchange and the AQUIS Growth Market (the “Exchanges”). The Company has been subject to a cease-trade order issued by the Ontario Securities Commission since May 8, 2023, resulting from the Company’s inability to file its annual financial statements, management discussion and analysis and CEO and CFO certifications for the year ended December 31, 2022, and its common shares have also been suspended from trading on the Canadian Securities Exchange and the AQUIS Growth Market since that date. Based on the Company’s current financial condition and the anticipated proceeds of the Disposal, the Company no longer expects that it will be able to complete the steps necessary to lift the cease trade order on a timely basis or at all, and notes that it may be subject to delisting from or other remedies by one or both of the Exchanges.
Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Feb 10Yooma Announces an Exit from Japan and Wind-Down of OperationsYooma Wellness Inc. provided a corporate update. The Company is engaged in an ongoing operational restructuring aimed at addressing depressed market conditions in the CBD wellness industry, the Company's increasing liquidity constraints and lack of working capital. The initial phases of this restructuring involved the wind-down of the Company's operations in the United States last year, and has gradually expanded to include the Company's operations in other unprofitable markets. In parallel with these restructuring initiatives, the Company has also been engaged in a continuing review of strategic alternatives for the Company, however, that process has to date been unsuccessful in identifying a path forward.
Reported Earnings • Dec 01Third quarter 2022 earnings released: US$0.006 loss per share (vs US$0.034 loss in 3Q 2021)Third quarter 2022 results: US$0.006 loss per share (improved from US$0.034 loss in 3Q 2021). Revenue: US$2.42m (up 14% from 3Q 2021). Net loss: US$624.8k (loss narrowed 76% from 3Q 2021).
Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 31Second quarter 2022 earnings released: US$0.011 loss per share (vs US$0.042 loss in 2Q 2021)Second quarter 2022 results: US$0.011 loss per share (up from US$0.042 loss in 2Q 2021). Revenue: US$3.29m (up 51% from 2Q 2021). Net loss: US$1.13m (loss narrowed 65% from 2Q 2021).
Board Change • May 26No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Sep 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
